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Abstract
Genome-wide association studies (GWAS) test hundreds of thousands of single-nucleotide
polymorphisms (SNPs) for association to a trait, treating each marker equally and ignoring prior
evidence of association to specific regions. Typically, promising regions are selected for further
investigation based on p-values obtained from simple tests of association. However, loci that exert
only a weak, low-penetrant role on the trait, producing modest evidence of association, are not
detectable in the context of a GWAS. Implementing prior knowledge of association in GWAS
could increase power, help distinguish between false and true positives, and identify better sets of
SNPs for follow-up studies.
Here we performed a GWAS on rheumatoid arthritis (RA) patients and controls (Problem 1, Genetic
Analysis Workshop 16). In order to include prior information in the analysis, we applied four methods
that distinctively deal with markers in candidate genes in the context of GWAS. SNPs were divided into a
random and a candidate subset, then we applied empirical correction by permutation, false-discovery
rate, false-positive report probability, and posterior odds of association using different prior probabilities.
We repeated the same analyses on two different sets of candidate markers defined on the basis of
previously reported association to RA following two different approaches. The four methods showed
similar relative behavior when applied to the two sets, with the proportion of candidate SNPs ranked
among the top 2,000 varying from 0 to 100%. The use of different prior probabilities changed the
stringency of the methods, but not their relative performance.
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Genome-wide association studies (GWAS) to identify
the genetic risk factors underlying complex disease are
now feasible thanks to advances in genotyping technol-
ogy and the development of commercial products
featuring panels with hundreds of thousands of single-
nucleotide polymorphisms (SNPs). A common approach
is to use the GWAS design to detect “promising” trait-
associated regions that could undergo further investiga-
tion. Typically, the top ranked markers are selected for
follow-up analysis based on p-values obtained from
simple tests of association, such as the 1 degree-of-
freedom chi-square test on allele frequency difference
between cases and controls. For several diseases, some
candidate genes may have already been identified by
linkage or association studies, or can be suggested on the
basis of functional or other biological, rather than
statistical, evidence. Such loci may exert only a weak,
low-penetrance role on the trait, producing modest
evidence of association. In the context of a genome-
wide study, the significance of markers in these regions
could be low and thus undetectable. GWAS typically
ignore any prior knowledge that may support evidence
of association to specific regions by treating each marker
equally. Incorporating this information into GWAS
could increase power, help distinguish between false
and true positives, and identify better informed sets of
SNPs for follow-up studies.
The HLA-DRB1 gene has long been known to be a major
rheumatoid arthritis (RA) susceptibility locus [1]. More
recently, variants of the PTPN22 gene have been reported
to be associated to RA [2,3]. Common genetic variants at
TRAF1 and C5 [4] and a haplotype at STAT4 have been
described in association to RA [5]. Besides these, several
other genes have been proposed and tested for associa-
tion to RA with controversial results.
Different ways to deal with markers in candidate genes in
the context of genome-wide studies have been suggested
[6-8]. Here we selected specific genomic regions as RA
candidate loci using two different approaches and
compared the relative performance of some of these
methods applied to the RA dataset analyzed by Plenge




On the basis of previously reported association to RA
and following two different approaches, we have defined
two sets of RA candidate markers: a more inclusive and
exhaustive “gene-based” set, and a more selective “SNP-
based” set.
Candidate Subset 1 included 64 genes defined as
associated to the broad phenotype of RA in the Genetic
Association Database [9,10]. SNPs included in the
prioritized subset were those located in a candidate
gene and a region of 5 kb on either side of it.
Set 2 was chosen through a review of recently (2006-
2008) published studies of RA [2-5]. Markers described
in these papers or in their references were included in the
Set 2. There were more than 50 SNPs reported as
showing association with RA, among which 24 SNPs
were genotyped in GAW16. These SNPs and 14
additional ones with pair-wise r2 with them greater
than 0.5 were selected, leading to a total of 38 candidate
SNPs. In addition, we searched RA-related SNPs from
NCBI OMIM database [11] and retrieved from the
HapMap data those SNPs whose pair-wise r2 with them
greater than 0.5, for a total of 51 genes. Thus, 89 SNPs
were included in the prioritized subset, and the remain-
ing SNPs were defined as the non-prioritized subset.
We excluded from all analyses the HLA region genes on
chromosome 6 (from 29,794,096 bp to 33,209,868 bp)
because HLA genes, and in particular DR alleles, have
already been unequivocally demonstrated to be strongly
associated to RA.
The genotypes at 545,080 SNPs from the Illumina 550k
chip were available for 868 North American Rheumatoid
Arthritis Consortium cases and 1194 controls. SNPs that
failed genotyping in more than 10% of all individuals or
presenting a minor allele frequency (MAF) lower than
1% were discarded. Missing genotypes at more than 10%
of markers was set as a sample exclusion condition, but
none of the individuals were removed.
After filtering for low MAF and low genotyping rate, and
excluding markers from the HLA region, 515,179 SNPs
remained. Of these, 681 SNPs localized in 55 candidate
genes in Set 1, and 72 were among the candidate SNPs in
Set 2. The complete lists of SNPs and genes included in
the two prioritized subsets are available from the
authors. The complementary subsets of markers were
considered to be random SNPs routinely genotyped in
GWAS.
Statistical methods
We have applied four different methods to prioritize
results from candidate regions in the context of a
genome-wide study, in addition to standard GWAS.
These methods included a Bayesian approach to calcu-
late posterior odds for association (henceforth referred
to as PO), assigning different prior probabilities to the
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selected candidate marker subset and to the routinely
genotyped marker subset [6]. Initially, we specified a
prior probability of p = 0.1 for the candidate region
markers and of p = 0.00018 for the other markers (PO1).
These values were chosen so that a candidate marker
significant at p = 0.01 and a routine marker significant at
p = 0.00001 yield similar values for the PO, as suggested
by Curtis et al. [6]. To investigate the effect of different
prior probabilities, we also assigned a less confident
prior probability of association of p = 0.01 to the
candidate SNPs subset (PO2).
Next we used the approach based on the false-positive
report probability (FPRP) described by Wacholder et al.
[7]. The FPRP is the probability of having no true
association between a genetic variant and disease given a
statistically significant finding. This can be calculated
based on the prior probability of real association, the
observed p-value, and the statistical power of the study,
which in turn depends on the sample size and the odds-
ratio under the alternative hypothesis. The odds-ratio
under the alternative hypothesis was fixed at 1.2 and two
different prior probabilities of 0.1 (FPRP1) and 0.01
(FPRP2) for candidate gene markers and 0.00018 for
random markers were considered. We used the formula
described by Wacholder et al. [7] to calculate the FPRP.
We also utilized a prioritized subset analysis (PSA) and
applied the false-discovery rate (FDR) procedure sepa-
rately to the subset of candidate markers and to the
complementary subset of random markers, as suggested
by Li et al. [8].
Finally, we calculated empirically corrected p-values by
permutation for the whole subset of random SNPs and
for the candidate SNP subset separately (henceforth
referred to as EMP), by swapping the case/control label
of individuals (assuming they are interchangeable under
the null). A total of 10,000 permutations were ran on
each SNP by means of the (max) T procedure imple-
mented in the software PLINK [12,13]. This procedure
controls for the number of SNPs tested by comparing
each observed test statistic against the maximum of all
permuted statistics (i.e., over all SNPs) for each single
replicate.
Standard case-control genome-wide association analysis
was carried out using the 1-df allelic test from PLINK
[13]. To implement the PO1 and PO2 procedures,
p-values were converted into PO values for association
using software provided by Curtis et al. [6,14]. The FPRP
was calculated using software provided by Wacholder
et al. [7]. To apply the FDR recommended by Li et al. [8],
the procedure described by Benjamini and Hochberg
[15] and implemented in PLINK was used.
Results
The genome-wide analysis conducted on the 515,179
SNPs that passed quality control revealed that 66 SNPs
were associated to RA with allelic test p-values < 10-7,
which remained significant at a = 0.05 after Bonferroni
correction for multiple tests. None of those SNPs was
located in any of the 55 selected candidate genes of Set 1,
while six were included in the candidate Set 2
(rs10760130, rs1953126, rs2900180, rs3761847, and
rs881375 in the region around TRAF1 on chromosome
9, and rs2476601 in PTPN22 on chromosome 1).
To identify regions worth of further analyses in follow-
up studies, we arbitrarily chose the first 2,000 SNPs
based on the ranking derived by the standard analysis
and the other approaches described in the Methods
section. Results thus obtained within each of the two
candidate sets are compared.
Candidate set 1
The 2,000 most significant SNPs following standard
genome-wide analysis had allelic test p-values that
ranged between 3.25 × 10-4 and 1.10 × 10-15. Even
though not significant at the genome-wide level, two
SNPs from this group were located in candidate genes,
specifically rs6435203 in CTL4A (p = 2.56 × 10-4) and
rs10480340 in TRB@ (p = 1.70 × 10-4).
When applying the FDR procedure separately in the
candidate SNP subset and in the complementary subset
of random markers [8], none of the candidate SNPs
ranked among the top 2,000 or had FDR < 0.05. The list
of the 2,000 top-ranked SNPs obtained by PSA/FDR was
almost identical to that obtained on the basis of their
nominal p-values. Following separate permutation ana-
lysis on the subset of random SNPs and on the candidate
SNP subset (EMP), only 575 SNPs showed an empirical
p-value lower than 1 and could thus be ranked, including
39 SNPs from 22 candidate genes. In the ranking based
on the PO values, specifying a prior probability of p = 0.1
for candidate gene markers and of p = 0.00018 for the
other routinely genotyped markers [6], 348 of the 2,000
top ranked SNPs were located in 49 of the candidate
genes. Using a prior probability of p = 0.01 for the
candidate gene markers reduced their number to 40
SNPs from 19 genes. All 681 candidate gene SNPs (with
just one with FPRP less than 0.05) were included in the
top 2,000 markers using FPRP1, and only 152 using
FPRP2 [7] (Figure 1).
In conclusion, 3,318 different SNPswere ranked among the
first 2,000 SNPs by at least one method, including all 681
SNPs located on the selected candidate genes. Only 345
SNPs were ranked among the top 2,000 by all methods,
and none of these were located on a candidate gene.
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Candidate set 2
Nine candidate SNPs from Set 2 were among the top
2,000 SNPs ranked with the standard genome-wide
analysis.
The PSA/FDR method increased the number of candidate
SNPs among the top ranked to 29, with the inclusion of
20 additional SNPs, with nominal p-values ranging from
3 × 10-2 to 1 × 10-12. Of these, 26 had FDR < 0.05, while
in the standard analysis only eight candidate SNPs had
significant FDR.
Ranking based on p-values empirically corrected by
permutation for the subsets of non-candidate and
candidate SNPs separately raised the number of candi-
date SNPs among the top ranked SNPs to 39, including
11 with empirical p-values lower than 0.05. In this
analysis, the total number of SNPs with empirical
p-values lower than 1 was 500.
The number of top-ranked candidate SNPs further
increased to 62 based on the POs ranking under PO1.
Under PO2, this number was only 28.
Using FPRP1, all 72 candidate SNPs were included
among the top 2,000, although only 14 had FPRP < 0.05.
When the prior probability of the candidate SNPs was
changed to 0.01 (FPRP2), only 36 of them were retained.
In conclusion, the PO method was more stringent than
the FPRP method under both sets of prior probabilities
(Figure 1).
Overall, 2,798 different SNPs were ranked among the
first 2,000 SNPs by at least one method, including all 72
candidate SNPs. Nine candidate SNPs in particular were
among the 319 SNPs ranked among the top 2,000 by all
methods.
Discussion
With respect to selection of SNPs for follow-up studies,
the standard genome-wide analysis yielded the lowest
number of candidate SNPs among the top 2,000 for all
the methods applied to Set 2, while the PSA/FDR method
was even less inclusive for Set 1. The application of
methods designed to prioritize results from selected
regions generally increased the number of candidate
SNPs that would undergo follow-up analyses. The four
methods showed the same relative performance in the
two candidate subsets, with the PSA/FDR approach being
the least inclusive, followed by the empirical correction
performed separately on the candidate subsets and the
random subsets, and finally by the POs method using
the prior probability p = 0.1. In both candidate subsets,
the FPRP approach with prior probability set at 0.1 ranked
all candidate SNPs among the top 2,000 markers and was
thus more permissive than the other methods.
The prior probabilities used for PO1 and FPRP1 (0.1 for
candidate SNPs and 0.00018 for random SNPs) result in
a 556-fold greater confidence on causality of candidate
SNPs compared to random SNPs. To evaluate the impact
of these parameters, we also considered a less confident
prior for the candidate SNP of p = 0.01. Under these
conditions, PO2 and FPRP2 were less inclusive, as
expected, yielding an even smaller number of candidate
SNPs among the top 2,000 than EMP. However, their
relative performance remained unchanged.
The different methods in Set 2 provided more homo-
genous results than in Set 1 (Figure 1). The number of
candidate SNPs that were ranked among the top 2,000 by
the different methods ranged from 0 to 681 (100%) in
Set 1, and from 28 (39%) to 72 (100%) in Set 2. When
ranking the top 1,000 SNPs only, those figures ranged
from 0% to 63% in Set 1 and from 28% to 97% in Set 2,
indicating that the candidate SNPs from Set 2 were more
highly ranked on average than those from Set 1. In
addition to comprising a smaller number of SNPs, our
hypothesis is that this may be due to the fact that Set 2
included stronger candidates following a more careful
review of the recent literature, while Set 1 included every
Figure 1
Top ranked SNPs detected by each method. Venn
diagram with the number of candidate SNPs ranked among
the top 2,000 markers by each method in Candidate Sets 1
(A) and 2 (B). GWA, standard allelic test; FDR, PSA followed
by FDR [8]; EMP, PSA followed by empirical correction; PO1
and PO2, posterior odds [6] with prior probabilities for
candidate SNPs of 0.1 and 0.01; FPRP1 and FPRP2, false-
positive report probability [7] with prior probabilities for
candidate SNPs of 0.1 and 0.01.
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gene reported at least once in the literature as associated
to RA. Specifically, Set 2 was SNP-based, so that actual
SNPs reported as associated with RA were investigated (or
SNPs in linkage disequilibrium with them), while Set 1
was gene-based, so that SNPs localized in a candidate
gene, but not necessarily related to RA, could have
lowered the power to detect association. As a matter of
fact, only 10% of SNPs from the Candidate Set 1 had
nominally significant p-values < 0.05, while 42% of SNPs
from Set 2 were nominally significant at the same a.
Bayesian methods are particularly intriguing as a way to
deal with multiple tests in GWAS. It has been claimed
that in interpreting observed associations the prior
credibility of the hypotheses is more relevant than the
number of tests performed [16]. The methods by Curtis
et al. [6] and Wacholder et al. [7], while inspired by a
Bayesian approach, are not fully Bayesian. They do not
specify a prior distribution for the effect size, which is
assumed as known in the FPRP method (dichotomized
as presence or absence of effect) [7]. Curtis et al. [6]
instead used the ratio of likelihoods maximized under
the alternative and null hypotheses as proxies for the
distribution that would have been obtained over the
universe of alternative and null hypotheses. In this light,
additional methods, such as the Bayesian false-discovery
probability recently proposed by Wakefield et al. [17]
should be considered and investigated as an interesting
alternative approach.
Conclusion
The results obtained here are dependent on a number of
arbitrary choices, such as the set of candidate genes and
SNPs selected, the prior probabilities used in the
analyses, and the number of SNPs selected for follow-
up analyses. Given the present conditions, the relative
performance of the methods tested was similar in the
two candidate subsets, even though the selection criteria
for the two sets were very different. However, in neither
of the two candidate subsets do we know which variant
is truly disease-associated. Thus we cannot say if the
association with candidate markers detected using these
methods reflects a real increase in power to detect weak
but true association. More detailed analyses of simulated
data under different scenarios for variable ranges of the
model parameters are needed to better evaluate these
methods’ relative performances.
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